Trecia A Wouldes1, Linda L Lagasse2, Marilyn A Huestis3, Sheri Dellagrotta4, Lynne M Dansereau5, Barry M Lester6. 1. Department of Psychological Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand. Electronic address: t.wouldes@auckland.ac.nz. 2. Brown Center for the Study of Children at Risk, Warren Alpert Medical School at Brown University, 101 Dudley Street, Providence, RI 02905, USA. Electronic address: Linda_LaGasse@brown.edu. 3. Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, 251 Bayview Boulevard, Suite 200, Room 05A-721, Baltimore, MD 21224, USA. 4. Brown Center for the Study of Children at Risk, Warren Alpert Medical School at Brown University, 101 Dudley Street, Providence, RI 02905, USA. Electronic address: SDellaGrotta@Wihri.org. 5. Brown Center for the Study of Children at Risk, Warren Alpert Medical School at Brown University, 101 Dudley Street, Providence, RI 02905, USA. Electronic address: LDansereau@Wihri.org. 6. Brown Center for the Study of Children at Risk, Warren Alpert Medical School at Brown University, 101 Dudley Street, Providence, RI 02905, USA. Electronic address: Barry_Lester@brown.edu.
Abstract
BACKGROUND: Despite the evidence that women world-wide are using methamphetamine (MA) during pregnancy little is known about the neurodevelopment of their children. DESIGN: The controlled, prospective longitudinal New Zealand (NZ) Infant Development, Environment and Lifestyle (IDEAL) study was carried out in Auckland, NZ. Participants were 103 children exposed to MA prenatally and 107 who were not exposed. The Mental Developmental Index (MDI) and the Psychomotor Developmental Index (PDI) of the Bayley Scales of Infant Development, Second Edition (BSID-II) measured cognitive and motor performances at ages 1, 2 and 3, and the Peabody Developmental Motor Scale, Second Edition (PDMS-II) measured gross and fine motor performances at 1 and 3. Measures of the child's environment included the Home Observation of Measurement of the Environment and the Maternal Lifestyle Interview. The Substance Use Inventory measured maternal drug use. RESULTS: After controlling for other drug use and contextual factors, prenatal MA exposure was associated with poorer motor performance at 1 and 2 years on the BSID-II. No differences were observed for cognitive development (MDI). Relative to non-MA exposed children, longitudinal scores on the PDI and the gross motor scale of the PDMS-2 were 4.3 and 3.2 points lower, respectively. Being male and of Maori descent predicted lower cognitive scores (MDI) and being male predicted lower fine motor scores (PDMS-2). CONCLUSIONS: Prenatal exposure to MA was associated with delayed gross motor development over the first 3 years, but not with cognitive development. However, being male and of Maori descent were both associated with poorer cognitive outcomes. Males in general did more poorly on tasks related to fine motor development.
BACKGROUND: Despite the evidence that women world-wide are using methamphetamine (MA) during pregnancy little is known about the neurodevelopment of their children. DESIGN: The controlled, prospective longitudinal New Zealand (NZ) Infant Development, Environment and Lifestyle (IDEAL) study was carried out in Auckland, NZ. Participants were 103 children exposed to MA prenatally and 107 who were not exposed. The Mental Developmental Index (MDI) and the Psychomotor Developmental Index (PDI) of the Bayley Scales of Infant Development, Second Edition (BSID-II) measured cognitive and motor performances at ages 1, 2 and 3, and the Peabody Developmental Motor Scale, Second Edition (PDMS-II) measured gross and fine motor performances at 1 and 3. Measures of the child's environment included the Home Observation of Measurement of the Environment and the Maternal Lifestyle Interview. The Substance Use Inventory measured maternal drug use. RESULTS: After controlling for other drug use and contextual factors, prenatal MA exposure was associated with poorer motor performance at 1 and 2 years on the BSID-II. No differences were observed for cognitive development (MDI). Relative to non-MA exposed children, longitudinal scores on the PDI and the gross motor scale of the PDMS-2 were 4.3 and 3.2 points lower, respectively. Being male and of Maori descent predicted lower cognitive scores (MDI) and being male predicted lower fine motor scores (PDMS-2). CONCLUSIONS: Prenatal exposure to MA was associated with delayed gross motor development over the first 3 years, but not with cognitive development. However, being male and of Maori descent were both associated with poorer cognitive outcomes. Males in general did more poorly on tasks related to fine motor development.
Authors: Kirsten R Heineman; Sacha La Bastide-Van Gemert; Vaclav Fidler; Karin J Middelburg; Arend F Bos; Mijna Hadders-Algra Journal: Dev Med Child Neurol Date: 2010-04-30 Impact factor: 5.449
Authors: Linda L LaGasse; Trecia Wouldes; Elana Newman; Lynne M Smith; Rizwan Z Shah; Chris Derauf; Marilyn A Huestis; Amelia M Arria; Sheri Della Grotta; Tara Wilcox; Barry M Lester Journal: Neurotoxicol Teratol Date: 2010-07-06 Impact factor: 3.763
Authors: Sheri Della Grotta; Linda L LaGasse; Amelia M Arria; Chris Derauf; Penny Grant; Lynne M Smith; Rizwan Shah; Marilyn Huestis; Jing Liu; Barry M Lester Journal: Matern Child Health J Date: 2009-06-30
Authors: L Chang; C Cloak; C S Jiang; S Farnham; B Tokeshi; S Buchthal; B Hedemark; L M Smith; T Ernst Journal: Neuroimage Date: 2009-07-01 Impact factor: 6.556
Authors: Lynne M Smith; Linda L Lagasse; Chris Derauf; Penny Grant; Rizwan Shah; Amelia Arria; Marilyn Huestis; William Haning; Arthur Strauss; Sheri Della Grotta; Melissa Fallone; Jing Liu; Barry M Lester Journal: Neurotoxicol Teratol Date: 2007-10-03 Impact factor: 3.763
Authors: Arijit Chakraborty; Nicola S Anstice; Robert J Jacobs; Nabin Paudel; Linda L LaGasse; Barry M Lester; Trecia A Wouldes; Jane E Harding; Benjamin Thompson Journal: Vision Res Date: 2015-09-02 Impact factor: 1.886
Authors: Fleur L Warton; Ernesta M Meintjes; Christopher M R Warton; Christopher D Molteno; Nadine M Lindinger; R Colin Carter; Lilla Zöllei; Pia Wintermark; Joseph L Jacobson; Andre van der Kouwe; Sandra W Jacobson Journal: Neurotoxicol Teratol Date: 2017-10-22 Impact factor: 3.763
Authors: Arijit Chakraborty; Nicola S Anstice; Robert J Jacobs; Nabin Paudel; Linda L LaGasse; Barry M Lester; Christopher J D McKinlay; Jane E Harding; Trecia A Wouldes; Benjamin Thompson Journal: Vision Res Date: 2017-04-28 Impact factor: 1.886
Authors: Arijit Chakraborty; Nicola S Anstice; Robert J Jacobs; Linda L LaGasse; Barry M Lester; Trecia A Wouldes; Benjamin Thompson Journal: Sci Rep Date: 2015-11-19 Impact factor: 4.379
Authors: Essi Heinonen; Barbara Szymanska-von Schultz; Viktor Kaldo; Josefine Nasiell; Ewa Andersson; Mikaela Bergmark; Margareta Blomdahl-Wetterholm; Lisa Forsberg; Erik Forsell; Anna Forsgren; Sandra Frööjd; Amy Goldman; Eva-Mari Nordenadler; Myrto Sklivanioti; Mats Blennow; Katarina Wide; Lars L Gustafsson Journal: BMJ Open Date: 2018-08-05 Impact factor: 2.692